Modulation of anthracycline activity in canine mammary tumour cells in vitro by medroxyprogesterone acetate

Research in Veterinary Science

Volumn 69, Issue 3, 2000, Pages 255-262

  Pagnini, Ugo ^a,b   Florio, S ^b   Lombardi, P ^b   D'Angelo, D ^b   Avallone, L ^c   Galdiero, M ^a   Iovane, G ^a   Tortora, G ^b   Pagnini, G ^b  

^a Special Section of Surgical Digestive Endoscopy   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; IDARUBICIN; MEDROXYPROGESTERONE ACETATE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOG; DRUG EFFECT; FEMALE; LIPID PEROXIDATION; MEMBRANE FLUIDITY; NONHUMAN; POLARIZATION; VISCOSITY;

EID: 0034493090     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1053/rvsc.2000.0421     Document Type: Article

References (75)

1. ANDREWS, P.A. & HOWELL, S.B. (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 21, 35-43
2. BENCHEKROUN, N. & ROBERT, J. (1992) Measurement of doxorubicin induced lipid peroxidation under the conditions that determine cytotoxicity in cultured tumour cells. Analytical Biochemistry 201, 326-330
3. BENCHEKROUN, N., POURQUIER, P., SCHOTT, B. & ROBERT, J. (1993) Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumour cell lines selected for resistance for doxorubicin. European Journal of Biochemistry 211, 141-146
4. BOUCEK, R.J., OLSON, R.D., BRENNER, D.E., OGUNBUNMI, E.M., INUI, M. & FLEISCHER, S. (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane associates ions pumps. A correlative study of cardiac muscle with isolated membrane fractions. Journal of Biological Chemistry 262, 15851-15856
5. CARMICHAEL, J., DE GRAFF, W.G., GADZR, A.F., MIUNA, J.D. & MITCHELL, J.B. (1987) Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Research 47, 936-942
6. CAVALLI, F., GOLDHIRSCH, A., JUNGI, F., MARTA, G., MERMILLOD, B. & ALBERTO, F. (1984) Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. Journal of Clinical Oncology 2, 414-419
7. CHANDLER, L.J., KOPNISKY, K., RICHARDS, E., CREWS, F.T., & SUMNERS, C. (1995) Angiotensin II decreases inducible nitric oxide synthase expression in rat astroglial cultures. American Journal of Physiology 268, C700-C707
8. COPPOC, G.L. (1991) Chemiotrapia delle malattie neoplastiche In: Farmacologia e Terapeutica Veterinaria Eds. N.H. Booth & L.E. McDonald. Roma: EMSI. pp. 947-966
9. CUMMINGS, J., WILLMOTT, N., HOEY, B.M., MARLEY, E.S., & SMYTH, J.F. (1992) The consequences of doxorubicin quinone reduction in vivo in tumour tissue. Biochemical Pharmacology 44, 2165-2174
10. DALTON, W.S. (1993) Drug resistance: modulation in the laboratory and clinic. Seminars in Oncology 20, 64-69
11. DENIZOT, F. & LANG R. (1986) Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. Journal of Immunological Methods 39, 271-277
12. DUENAS-GONZALEZ, A., ISALES, C.M., del MAR ABAD-HERNANDEZ, M., GONZALEZ-SARMIENTO, R., SANGUEZA, O., & RODRIGUEZ-COMMES, J. (1997) Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. Modern Pathology 10, 645-649
13. DUVAL, D., DURANT, S., & HOMO DELARCHE, F. (1983) Non genomic effects of steroids. Interaction of steroid molecules with membrane structures and functions. Biohimica Biophysica Acta 737, 409-442
14. ENGEL, L.W. & YOUNG, N.A. (1978) Human breast carcinoma cells in continuous culture: a review. Cancer Research 38, 4327-4339
15. EORTC (European Organization for Research and Treatment Cancer) (1980) Breast Cancer Cooperative Group: revision of the standards for the assessment of hormone receptors in human breast cancer. European Journal of Cancer 16, 1513-1516
16. ESTERBAUER, H. & CHEESEMAN, K.H. (1990) Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods in Enzymology 186, 407-421
17. FABER, M., COUDRAY, C., HIDA. H., MOUSSEA, U M. & FAVIER A. (1995) Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy including adriamycin. Biological Trace Element Research 47, 117-123
18. FLEMING, G.F. AMATO, J.M., AGRESTI, M. & SAFA, A.R. (1992) Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chemotherapy and Pharmacology 29, 445-449
19. FLORIO, S., PAGNINI, D., CRISPINO, A., AVALLONE, L., LOMBARDI, R. ZUCCARO, S., LANNI, C., & PELAGALLI A. (1996) Preliminary observation on the interference of antiblastic agents in membrane fluidity and leukocyte potential. Journal of Chemotherapy 81, 399-402
20. GARCIA ZEVALLOS, M. & FARKAS T. (1989) Manipulation of plasma membrane physical state affects desaturase activity in rat lymphocytes. Archives of Biochemistry and Biophysics 271, 546-552
21. GARNER, A.P., PAINE, M.J., RODRIGUEZ-CRESPO, I., CHINJE, E.C., ORTIZ DE MONTELLANO, P., STRATFORD, I.J., TEW, D.G. & WOLF, C.R. (1999) Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Research 59, 1929-1934
22. GERMAIN, E., CHAJÈS. V., COGNAULT, S., LHUILLERY, C. & BOUGNOUX, P. (1998) Enhancement of doxorubicin cytotoxicity by polyunsatured fatty acids in the human breast tumour cell line MDA-MB-231: relationship to lipid peroxidation. International Journal of Cancer 75, 578-583
23. GOODMAN, J., & HOCHSTEIN, P. (1977) Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochemical and Biophysical Research Communications 77, 797-803
24. HABERL, I., SWATONEK, H., SCHAUFLER, K., ULEPERGER, E., WENZL, E., THEYER, G., HAMILTON, G. & THALHAMMER, T. (1998) P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro. International Journal of Oncology 12, 1137-1142
25. HELLMEN, E. (1992) Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumour cell lines. In Vitro Cell Developmental Biology 28A, 309-319
26. HUPPERETS, P.S., WILS, J., VOLOVICS, L., SCHUTEN, L., PICKERS, M., BRON, H., SCHOUTEN, H.C., JAGER, J., SMEETS, J. & DE JONG, J. (1993) Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracile (CAF) with or without medroxyprogesterone acetate for node positive breast cancer patients. Annals of Oncology 41, 295-301
27. IACOBELLI, S., SICA, G., NATOLI, C. & GATTI, D. (1983) Inhibitory effects of medroxyprogesterone acetate on the proliferation of human breast cancer cells. (1983) In: Role of Medroxyprogesterone Acetate in Endocrine Related Tumors, Vol. II, Eds. L Campio. G. Robustelli Della Cuna & R.W. Taylor. New York: Raven Press p. 1-6
28. INAGAKI, R., TANIGUCHI, T., SAKAI, T., HAYASHI, N., ISHII, Y. & MURAMATSU, I. (1999) Anticancer drugs inhibit induction of NO Synthase in rat in vivo. General Pharmacology 32, 185-188
29. ISHIDA, H., OKABE, M., GOMI, K., HORIUCHI, R., MIKAMI, K. NAITO, M. & TSUMO, T. (1994) Modulation of adriamycin resistance in human breast carcinoma MCF-7 cells in vitro and in vivo by medroxyprogesterone acetate. Japanese Journal Cancer Research 85, 542-549
30. KANTROWITZ, N.E., & BRISTOW, M.R. (1984) Cardiotoxicity of antitumour agents. Progress in Cardiovascular Disease 27, 195-200
31. KAVE, S.B. (1993) P-glycoprotein (P-gp) and drug resistance-time for reappraisals. British Journal of Cancer 67, 703-707
32. KELLER, E.T., MACEWEN, E.G., ROSENTHAL, R.C., HELFAND, S.C., & FOX, L.E. (1993) Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. Journal of Veterinary Internal Medicine 7, 289-295
33. LECUREUR, V. FARDEL, O., & GUILLOUZO, A. (1994) The antiprogestatin drug RU-486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS-letter 355, 187-191
34. rd. (1997) Nitric oxide contributes to adriamycin's antitumor effect. Journal of Surgical Research 69, 283-287
35. LOMBARDI, P., FLORIO, S., PAGNINI, U., CRISPINO, A. & AVALLONE, L. (1999) Ovarian function suppression with a GnRH analogue: D-ser(But[t])[6]-Arzgly[10]-LHRH (Goserelin) in hormone dependent canine mammary cancer. Journal of Veterinary Pharmacology and Therapeutics 22, 56-61
36. LOWRY, O.H., ROSEMBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951) Protein mesurement with the folin phenol reagent. Journal of Biological Chemistry 193, 265-275
37. LUO D., & VINCENT, S.R. (1994) Inhibition of nitric oxide synthase by antineoplastic anthracyclines. Biochemical Pharmacology 47, 2111-2112
38. MAEDA, H. & AKAIKE, T. (1998) Nitric oxide and oxygen radicals in infection, inflammation and cancer. Biochemistry (Moscow) 63, 854-865
39. MANN, S.C., ANDREWS, P.A. & HOWELL, S.B. (1988) Comparision of lipid content, surface membrane fluidity, and temperature dependence of cisdiamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Research 8, 1211-1216
40. MANTOVANI, G., MACCIÒ, A., LAI, P., MASSA, E., GHIANI, M. & SANTONA, M.C. (1998) Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Seminars in Oncology 25, 24-52
41. MARUTAKA, M., IWAGAKI, H., SUGURI, T. TANAKA, N. & ORITA, K. (1994a) Alterations of membrane fluidity in K562 cells exposed to the anticancer drug adriamycin. Research Communications in Molecular Pathology and Pharmacology 85, 141-149
42. MARUTAKA, M., IWAGAKI, H., AOKI, H., SUGURI, T., TANAKA, N. & ORITA, K. (1994b) The extracellular pH and membrane fluidity on intracellular retention of adriamycin. Gan To Kagaku Ryoho 21, 2415-2419
43. MATHERNE, C.M., SATTERFIELD, W.C., GASPARINI, A., TONETTI, M., ASTROFF, A.B., SCHMIDT, R.D., ROWE, L.D., & DeLOACH, J.R. (1994) Clinical efficacy and toxicity of doxorubicin encapsulate in glutaraldehydetreated erythrocytes administered to dogs with lymphosarcoma. American Journal of Veterinary Research 7, 370-376
44. MEALY, K.L., BARHOUMI, R. ROGERS, K., & KOCHEVAR, D.T. (1998) Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line. Cancer Letter 126, 187-192
45. MERLIN, J.L., GUERCI, A., MARCHAL, S., MASSOUM, N., RAMACCI, C., HUMBERT, J.C., TSURUO, T. & GUERCI, O. (1994) Comparative evaluation of S9788, verapamil and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 84, 262-269
46. MOULTON, J.E. (1990) Tumours of mammary gland. In: Tumours in Domestic Animals Ed. J.E. Moulton Berkeley: University of California Press, pp. 518-552
47. NORVALL, M., ELSE, R.W. & MAINGAY, J. (1988) The effect of tamoxifen on tumours induced by cells from a canine mammary carcinoma cell line in athymic nude mice. Research in Veterinary Science 44, 76-81
48. OHSHIMA, H., & BARTSCH, H. (1994) Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutation Research 305, 253-264
49. PACILIO, C., FLORIO, S., PAGNINI, U., CRISPINO, A., CLAUDIO, P.P., PACILIO, G. & PAGNINI, G. (1998) Modification of membrane fluidity and depolarization by some anthracyclines on different cell lines. Interference by Medroxyprogesterone acetate and Verapamil. Anticancer Research 18, 4027-4034
50. PASQUALINI, J.R., PARIS, J., STRUK-WARE, R., CHETRITE, G. & BOTELLA, J. (1998) Progestins and breast cancer. Journal of Steroid Biochemistry and Molecular Biology 65, 225-235
51. POWIS, G. (1989) Free radical formation by antitumor quinones. Free Radical Biology and Medicins 6, 63-101
52. PRAET, M., STRYCKMANS, P. & RUYSSCHAERT, J.M. (1996) Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells. Biochemical Pharmacoloy 51, 1341-1348
53. RINTOUL, D.A. & CENTER, M.S. (1984) Involvement of plasma membrane lipid structural order in adryamicin resistance in Chinese hamster lung cells. Cancer Research 44, 4978-4980
54. SARTIN, E.A., BARNES, S., TOIVIO-KINNUCAN, M. WRIGHT, J.C. & WOLFE, L.G. (1993) Heterogenic proprieties of clonal cell lines derived from canine mammary carcinoma and sensitivity to tamoxifen and doxorubicin. Anticancer Research 13, 229-236
55. SCATCHA,RD G. (1949) The attraction of proteins for small molecules and ions. Annals of the New York Academy of Sciences 51, 660-672
56. SELMAN, R.J., WOLFSWINKEL, J. & MOL, J.A. (1996) Binding specificity of medroxyprogesterone acetate and proligestone for the progesterone and glucocorticoid receptor in dog. Steroids 61, 133-137
57. SIEGFRIED, J.A., BURKE, T.G. & TRITTON, T.R. (1985) Cellular transport of anthracyclines by passive diffusion. Implication for drug resistance. Biochemical Pharmacology 34, 593-598
58. SIKIE, B.I. (1993) Modulation of multidrug resistance: at the threshold. Journal of Clinical Oncology 11, 1629-1635
59. SONNEVEL, P. DURIE, B.G., LOKHURST, H.M., MARIE, J.P., SOLBU, G., SUCIU, S., ZITTOUN, R., LOWENBERG, G. & NOORE, K. (1992) Modulation of multi-drug resistant multiple myeloma by ciclosporin. Lancet 340, 255-259
60. SPEELMANS, G., STAFFHORST, R.W., de KRUIJFF, B. & de WOLF, F.A. (1994) Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflets of the plasma membrane. Biochemistry 33, 13761-13768
61. STEINGOLD, S.F. SHARP, N.J., McGAHAN, M., HUGHES, C.S., DUNN, S.E. & PAGE, R.L. (1998) Characterization of canine MDRI mRNA: its abundance in drug resistant cell lines and in vivo. Anticancer Research 18(1A) 393-400
62. SUGINO, N., KASHIDA, S., TAKIGUCHI, S., NAKAMURA Y,. & KATO, H. (2000) Induction of superoxide dismutase by decidualization in human endometrial stromal cells. Molecular Human Reproduction 6, 178-184
63. SVINGEN, B.A. & POWIS, G. (1981) Pulse radiolysis studies of antitumor quinones: radical lifetimes, reactivity with oxygen, and one-electron reduction potentials. Archives of Biochemistry and Biophysics 209, 119-126
64. TARASIUK, J., FREZARD, F. & GARNIER-SUILLEROT, A. (1989) Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. Biochimica et Biophysica Acta 1013, 109-117
65. TATEYAMA, S., FURAKAWA, H., YAMAGUCHI, R. & NOSAKA, D. (1990) Plate and collagen-gel cultures of normal canine mammary epithelial cells. Research in Veterinary Science 49, 14-19
66. TRANQUILLI A., L., MAZZANTI, L., CUGINI, A.M., CESTER, N., GARRETTI, G.G. & ROMANICI C. (1995) Transdermal estradiol and medroxyprogesterone acetate in hormon replacement therapy are both antioxidants. Gynecologycal Endocrinology 9, 137-141
67. VAN BOMMEL, T., MARSEN, T. & BOJAR, H. (1987) Effects of high-dose medroxyprogesterone acetate and varions other steroid hormones on plasma membrane lipid mobility in CAMA-1 mammary cancer cells. Anticancer Research 7, 1217-1224
68. VAN VEELEN, H., WILLIEMSE, P.H., SIEIJFER, D.T., VAN DER PLOEG, E., SLUITER, W.I. & DOORENBOS, H. (1985) Mechanism of adrenal suppression by high dose medroxyprogesterone acetate in breast cancer patients. Cancer Chemotherapy and Pharmacology 15, 167-170
69. VASQUEZ-VIVAR, J., MARTASEK, P., HOGG, N., MASTERS, B.S.S., PRITCHARD, K.A. Jr. & KALYANARAMAN, B. (1997) Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 36, 11293-11297
70. VENDITTI, P., BALESTRIERI, M., DE LEO, T. & DI MEO, S. (1998) Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovascular Research 38, 695-702
71. WANG, L., YANG, C.P.H., HORWITZ, S.B., TRAIL, P.A. & CASAZZA, A.M. (1994) Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate. Cancer Chemotherapy and Pharmacology 34, 96-102
72. WHEELER, C., RADER, R. & KESSEL, D. (1982) Membrane alterations associated with progressive adriamycin resistance. Biochemical Pharmacology 31, 2691-2693
73. WINK, D.A. & MITCHELL, J.B. (1998) Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radicals Biology and Medicine 25, 434-456
74. YAMASHITA, J., HIDESHIMA, T. SHIRAKUSA, T. & OGAWA, M. (1996) Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma. Cancer 78, 2346-2352
75. ZIBERA, C., GIBELLI, N., MAESTRI, L. & ROBUSTELLI DELLA CUNA, G. (1995) Medroxyprogesterone acetate reverses the MDR phenotype of the CG5-doxorubicin resistant human breast cancer cell line. Anticancer Research 15, 745-750